A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Phase 4

Completed

• Conditions: Meningococcal Meningitis
• Interventions: Biological: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine; Biological: MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine

• Registration Number: NCT01424644
• Lead Sponsor: Novartis

Brief Summary

The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by these vaccines when given alone.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-08-23
• Study First Submitted QC: 2011-08-26
• Study First Posted: 2011-08-29
• Study Start: 2011-09
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Results First Submitted: 2013-11-20
• Status Verified: 2014-01
• Results First Submitted QC: 2014-01-21
• Last Update Submitted: 2014-01-21
• Results First Posted: 2014-02-14
• Last Update Posted: 2014-02-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 801

Inclusion Criteria

Individuals eligible for enrollment in this study were female and male individuals who had been shown to be healthy and who were:

1. 11-18 years of age inclusive who had given their written consent/assent and if applicable, whose parents or legal guardians had given written informed consent at the time of enrollment;

   • Available for all visits and telephone calls scheduled for the study;

   • In good health as determined by:

     • Medical history
     • Physical assessment
     • Clinical judgment of the investigator

2. Had been properly vaccinated against diphtheria, tetanus, and pertussis per local regulations;

3. Subjects who were current with childhood DTP-containing vaccinations per local guidelines. Any previous vaccinations containing DTP must have been received at least 5 years before study enrollment and no prior adolescent vaccinations (11-18 years of age) containing DTP vaccines were allowed.

4. For female subjects, who had a negative urine pregnancy test.

5. Any female subject who is sexually active committed to practice appropriate birth control.

Exclusion Criteria

Individuals not eligible to be enrolled in the study were those:

1. Who were unwilling to give their written assent / consent

2. Who were breastfeeding

3. Who was, and/or whose parents or legal guardians were perceived to be unreliable or unavailable for the duration of the study period

4. Who had previous confirmed or suspected disease caused by N. meningitidis

5. Who had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis infection within 60 days prior to enrollment

6. Who had previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or investigational). (Exception: Receipt of OMP-containing Hib vaccines was permitted)

7. Who had received prior human papillomavirus (HPV) vaccine

8. Who had received investigational agents or vaccines within 30 days prior to enrollment or who expected to receive an investigational agent or vaccine prior to completion of the study

9. Who had received live licensed vaccines within 30 days and inactive vaccine within 15 days prior to enrollment or for whom receipt of a licensed vaccine is anticipated during the study period.

   (Exception: Influenza vaccine could be administered up to 15 days prior to each study immunization and no less than 15 days after each study vaccination)

10. Who had experienced, within the 7 days prior to enrollment, significant acute or chronic infection (for example requiring systemic antibiotic treatment or antiviral therapy) or had experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to enrollment

11. Who had any serious acute, chronic or progressive disease such as

    • History of cancer
    • Complicated diabetes mellitus
    • Advanced arteriosclerotic disease
    • Autoimmune disease
    • HIV infection or AIDS
    • Blood dyscrasias
    • Congestive heart failure
    • Renal failure
    • Severe malnutrition (Note: Subjects with mild asthma were eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic corticosteroids were not eligible for enrollment)

12. Who had epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome

13. Who had a history of anaphylaxis, serious vaccine reactions, or allergy to any vaccine component, including latex allergy

14. Who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):

    • Receipt of immunosuppressive therapy within 30 days prior to enrollment (systemic corticosteroids administered for more than 5 days, or in a daily dose > 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy)
    • Receipt of immunostimulants
    • Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study

15. Who were known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;

16. Who have Down's syndrome or other known cytogenic disorders;

17. Who and/or whose families were planning to leave the area of the study site before the end of the study period;

18. Who had any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

19. Who were relatives of the study personnel.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo + Tdap + HPV	Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine	This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
MenACWY-CRM + Tdap + HPV	MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine	This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.

Primary Outcome Measures

Name	Time	Method
Geometric Mean Concentrations of Antibodies Against Pertussis Antigens After Concomitant Administration of Tdap With HPV and MenACWY-CRM Compared to Concomitant Administration of Tdap With HPV and Placebo	1 month post Tdap vaccination.	The geometric mean concentrations (GMCs) of antibodies against pertussis antigens (PT, FHA and PRN), as measured by ELISA, following concomitant administration of Tdap with HPV and MenACWY-CRM as compared to concomitant administration of Tdap with HPV and placebo.
Percentages of Subjects With Anti-diphtheria and Anti-tetanus Antibody Concentrations ≥ 0.1 IU/mL When Tdap is Administered Concomitantly With HPV and MenACWY-CRM Vaccine Compared to Tdap Given Concomitantly With HPV and Placebo	1 month post Tdap vaccination.	The percentages of subjects with anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL (as measured by ELISA) following concomitant administration of Tdap with HPV and MenACWY-CRM vaccine as compared to concomitant administration of Tdap with HPV and placebo.

Secondary Outcome Measures

Name	Time	Method
Number of Subjects With Solicited Local and Systemic Adverse Events When Tdap and HPV Are Concomitantly Administered With MenACWY-CRM Compared to When Tdap and HPV Are Concomitantly Administered With Placebo	Day 1-7 after any vaccination.	The number of subjects reporting solicited local and systemic reactions following concomitant administration of MenACWY-CRM vaccine, Tdap and HPV vaccine as compared to concomitant administration of placebo with Tdap and HPV.
Geometric Mean hSBA Titers Against N. Meningitidis Serogroups A,C,W and Y at 1 Month After Men ACWY Vaccination.	1 month post MenACWY-CRM vaccination.	The immunogenicity was assessed in terms of geometric mean hSBA titers of MenACWY when administered concomitantly with Tdap and HPV at 1 month after 1 dose of MenACWY vaccination.
Number of Subjects With Unsolicited Adverse Events When Tdap and HPV Are Concomitantly Administered With MenACWY-CRM Compared to When Tdap and HPV Are Concomitantly Administered With Placebo	Throughout the study (Day 1 to Day 211).	The number of subjects reporting any unsolicited adverse reactions (AEs) when Tdap and HPV are concomitantly administered with MenACWY-CRM as compared to when Tdap and HPV vaccine are concomitantly administered with placebo.; Note: A total of 2 MenACWY-CRM+Tdap+HPV subjects reported AEs leading to premature withdrawal - one subject due to treatment emergent AE and another subject prior to study vaccination on day 1.

Trial Locations

Locations (20)

Prairie Fields Family Medicine, 350 W. 23rd Street, Suite A; 🇺🇸 Fremont, California, United States

HOSPITAL"SAN MARTINO". Department of Health Sciences University of Genoa; 🇮🇹 Via Pastore, 1, Genoa, Italy

Clinical Research Advantage / Colorado Springs Health Partners, 6340 Barnes Road; 🇺🇸 Colorado Springs, Colorado, United States

Dayton Clinical Research, 1100 Salem Ave; 🇺🇸 Dayton, Florida, United States

Pediatrics and Adolescent Medicine, 120 Stonebridge Parkway, Suite 410; 🇺🇸 Woodstock, New York, United States

Pediatrics and Adolescent Medicine, 2155 Post Oak Tritt Road, Suite 100; 🇺🇸 Marietta, Georgia, United States

Clinical Research Advantage / Ridge Family Physicians, 201 Ridge Street, Suite 201; 🇺🇸 Council Bluffs, Iowa, United States

Columbia Medical Practice, 5450 Knoll North Drive, Suite 215; 🇺🇸 Columbia, Maryland, United States

Capitol Pediatrics and Adolescent Center, 3801 Computer Drive Suite 200; 🇺🇸 Raleigh, North Carolina, United States

Madera Family Medical Group, 1111 W. Fourth Street; 🇺🇸 Madera, California, United States

Roslindale Pediatrics Associates, 1153 Centre Street, Suite 31; 🇺🇸 Boston, Massachusetts, United States

Altamonte Pediatric Associates, 101 N. Country Club Rd. #113; 🇺🇸 Lake Mary, Florida, United States

Bellevue Family Practice, 2206 Longo Suite 201; 🇺🇸 Bellevue, Nebraska, United States

Ohio Pediatric Research Association, 7371 Brandt Pike Suite C; 🇺🇸 Huber Heights, Ohio, United States

Omega Medical Research, 400 Bald Hill Road; 🇺🇸 Warwick, Rhode Island, United States

Birmingham Pediatrics, 806 Saint Vincent's Drive, Suite 615; 🇺🇸 Birmingham, Alabama, United States

Hospital "Maggiore della Carità". Pediatric Clinic; 🇮🇹 Corso Mazzini, 18, Novara, Italy

Complete Children's Health, 8201 Northwoods Drive; 🇺🇸 Lincoln, Nebraska, United States

Hospital of Taranto- Unit of Hygiene and Publich Health Vaccination Center; 🇮🇹 Viale Magna Grecia, 173, Taranto, Italy

Meridian Clinical Research, 3319 North, 107th Street; 🇺🇸 Omaha, Nebraska, United States